Company profile
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ:SXTPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ARAKODA | approved | $0.2MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06656351 | phase2 | recruiting | 2025-11-18 | 2027-02-01 | 60 Degrees Pharmaceuticals LLC | B-FREE Chronic Babesiosis Study |
| NCT03320174 | phase2 | completed | 2017-10-05 | 2021-07-13 | 60 Degrees Pharmaceuticals LLC | Long-Term Safety Study of Tafenoquine |
| NCT06207370 | phase2 | recruiting | 2024-06-17 | 2027-03-01 | 60 Degrees Pharmaceuticals LLC | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis |
| NCT04533347 | phase2 | completed | 2021-02-19 | 2022-06-30 | 60 Degrees Pharmaceuticals LLC | Tafenoquine in Patients With Mild to Moderate COVID-19 |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 210607 | 2018-08-08 | NDA | 60 DEGREES PHARMACEUTICALS INC | |||||
Loading… | ||||||||